The last couple of days has seen some speculation about sanofi aventis' play for Genzyme. Big Pharma's acquisitiveness for biotech's not new - this is just the latest example. In the last decade (maybe a little more), biotech seems to have been having better luck than Big Pharma putting new drugs into the pipeline especially … Continue reading Sanofi’s play for Genzyme – stray thoughts
Apothecurry 